Evidence map›Paper›PMID 32458113›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Barriers to lung cancer referral, diagnosis, and treatment in Central America and the Caribbean: the health professionals' perspectives.

Aziza Maklouf-Quirós, Johayra Simithy, Kavita Ragoobar, Vivian Flores-Siles, Allan Ramos-Esquivel, Karen Villamil, Marianne Chacón-Araya

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aziza Maklouf-QuirósMedical Affairs Department, Roche Central America and the Caribbean, Heredia, Costa Rica.
Johayra SimithyMedical Affairs Department, Roche Central America and the Caribbean, Heredia, Costa Rica.
Kavita RagoobarMedical Affairs Department, Roche Central America and the Caribbean, Heredia, Costa Rica.
Vivian Flores-SilesMedical Affairs Department, Roche Central America and the Caribbean, Heredia, Costa Rica.
Allan Ramos-EsquivelDepartment of Pharmacology, School of Medicine, University of Costa Rica, P.O. Box 2082, San Pedro, San José, Costa Rica. allan.ramos@ucr.ac.cr.ORCID https://orcid.org/0000-0002-6633-771X
Karen VillamilMedical Affairs Department, Roche Central America and the Caribbean, Heredia, Costa Rica.
Marianne Chacón-ArayaPersonalized Healthcare, Genentech, South San Francisco, CA, 94080, USA.
Universidad de Costa Rica · CR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo identify the perspectives from healthcare providers about the limitations in referral, diagnosis, and treatment of lung cancer (LC) patients.

methodsA cross-sectional study through an Internet-based survey was addressed to physicians of multidisciplinary teams in charge of LC patients from Cuba, Curacao, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Jamaica, Panama, and Trinidad and Tobago. The questions focused on physicians' perspectives concerning waiting times and the availability of diagnostic and staging procedures in their settings, as well as the access to systemic therapies and continuous medical education (CME).

resultsA total of 152 physicians responded to the online questionnaire (response rate 24.9%). Delays in biopsy results were the main barrier for LC diagnosis as identified by 48.2% of the respondents, followed by patients not being referred in time (31.3%), delays for staging procedures (11.4%), and time taken for biopsy (9%). Almost one-half of physicians perceived that patients are diagnosed in advanced stages. A total of 29 respondent physicians (19.1%) reported limited access to immunohistochemical or genetic analysis for common mutations. Although 73 physicians (48.0%) confirmed that their centers provided radiotherapy and systemic therapy for their patients, immunotherapy was not available in the institutions of 30 physicians (19.7%). A total of 42 practitioners (27.6%) reported that they did not have access to CME on LC topics due to working or budget restrictions.

conclusionsThis study revealed among respondents the main barriers for an appropriate management of LC patients in the Central American and Caribbean Region. Further studies must validate these findings.

Indexed as

Lung NeoplasmsCaribbean RegionCentral AmericaCross-Sectional StudiesHealth PersonnelHumansReferral and ConsultationCaribbean regionCentral AmericaLung cancerReferral and consultation

Identifiers

PMID32458113
OpenAlexW3030592774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.